Send to

Choose Destination
See comment in PubMed Commons below
Arch Pediatr. 2012 Sep;19 Suppl 2:S61-4. doi: 10.1016/S0929-693X(12)71275-7.

[Meningococcal vaccines: from polysaccharide to conjugate vaccines].

[Article in French]

Author information

ACTIV-Association Clinique et Thérapeutique Infantile du Val de Marne, ACTIV, 27 rue Inkermann, 94100 Saint Maur des Fossés, France.


Vaccines against the polysaccharide meningococcal capsule lead to the prevention of invasive meningococcal diseases due to serotypes A, C, Y, W135. Polysaccharide vaccines, according to their immunological characteristics, could be used only to protect during a risk period relatively short: travel in endemic areas, epidemics and index cases. The dramatic success of the implementation of meningococcal C conjugate vaccines in England, and in several European countries has opened new perspectives. Three ACYW135 conjugate vaccines are or will soon be available. Meningococcal conjugate vaccines may be used for the same indications than polysaccharides vaccines, but also for long term individual protection (both for patient at high risk or without risk factor) and in national immunization programs. They must replace polysaccharide vaccines notably because of the risk of immunologic hypo-responsiveness.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center